Biomarkers in Tissue Samples From Patients With Ewing Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01480518
Recruitment Status : Completed
First Posted : November 29, 2011
Last Update Posted : May 12, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:

RATIONALE: Studying samples of tissue in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying biomarkers in tissue samples from patients with Ewing sarcoma.

Condition or disease Intervention/treatment
Sarcoma Genetic: DNA analysis Genetic: comparative genomic hybridization Genetic: gene expression analysis Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: polymorphic microsatellite marker analysis Other: laboratory biomarker analysis

Detailed Description:


  • To describe the spectrum of GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing sarcoma tumor specimens.
  • To determine if there are differences in GGAA-microsatellite polymorphisms in genomic DNA prepared from Ewing sarcoma tumor specimens as compared to non-afflicted European and African normal genomic DNA.
  • To determine if GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing's sarcoma tumor specimens correlates with disease outcome in patients treated on COG protocol AEWS0031.
  • To determine whether whole-genome amplification introduces alterations in GGAA-microsatellites as compared to non-amplified genomic DNA.

OUTLINE: Genomic PCR is used to amplify the microsatellites in the NR0B1 and GSTM4 promoters. In addition to determining microsatellite size, each microsatellite is sequenced following cloning into the pCR4 vector (Invitrogen) using standard topoisomerase cloning protocols.

Study Type : Observational
Actual Enrollment : 166 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Analysis of GGAA-Microsatellites in Ewing Sarcoma
Study Start Date : December 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Primary Outcome Measures :
  1. Event-free survival

Biospecimen Retention:   Samples With DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Ewing sarcoma.


  • Specimens from patients with Ewing sarcoma used for protocol COG-AEWS08B1

    • Obtained from patient samples taken from patients enrolled on COG-AEWS0031
    • Whole genome-amplified DNA will be used


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01480518

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Stephen Lessnick, MD, PhD University of Utah

Responsible Party: Children's Oncology Group Identifier: NCT01480518     History of Changes
Other Study ID Numbers: AEWS11B2
COG-AEWS11B2 ( Other Identifier: Children's Oncology Group )
AEWS11B2 ( Other Identifier: Children's Oncology Group )
NCI-2012-00083 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: November 29, 2011    Key Record Dates
Last Update Posted: May 12, 2015
Last Verified: May 2015

Keywords provided by Children's Oncology Group:
localized Ewing sarcoma/peripheral primitive neuroectodermal tumor

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue